Craft

Moderna

Stock Price

$117.3

2024-05-10

Market Capitalization

$45 B

2024-05-10

Revenue

$6.8 B

FY, 2023

Moderna Summary

Company Summary

Overview
Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine. It develops medicines infectious diseases, immuno-oncology, rare diseases and autoimmune diseases.
Type
Public
Status
Active
Founded
2010
HQ
Cambridge, MA, US | view all locations
Website
https://www.modernatx.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Stéphane Bancel

    Stéphane Bancel, Chief Executive Officer, Board Member

  • Tracey Franklin

    Tracey Franklin, Chief Human Resources Officer

  • Kate Cronin

    Kate Cronin, Chief Brand Officer

  • Shannon Thyme Klinger

    Shannon Thyme Klinger, Chief Legal Officer and Corporate Secretary

Operating MetricsView all

Program Expenses (Systemic Intracellular Therapeutics)

$4M
20.0%

Q1, 2022

Program Expenses (Cancer Vaccines)

$3M
82.4%

Q1, 2022

Patent Applications

430
28.3%

FY, 2021

LocationsView all

11 locations detected

  • Cambridge, MA HQ

    United States

    200 Technology Square

  • Melbourne, VIC

    Australia

    level 49/101 Collins St

  • Paris, IDF

    France

    19 Rue Cognacq Jay

  • München, BY

    Germany

    Rosenheimer Str. 143C

  • Tokyo, Tokyo

    Japan

    4-1-1 Toranomon, Minato-ku

  • Warszawa, Mazowieckie

    Poland

    Rondo Daszyńskiego 1

and 5 others

Moderna Financials

Summary Financials

Revenue (Q1, 2024)
$167.0M
Gross profit (Q1, 2024)
$71.0M
Net income (Q1, 2024)
($1.2B)
Cash (Q1, 2024)
$2.1B
EBIT (Q1, 2024)
($1.3B)
Enterprise value
$43.5B

Footer menu